Search

Your search keyword '"Kilpatrick, Trevor"' showing total 718 results
Start Over Author "Kilpatrick, Trevor"
718 results on '"Kilpatrick, Trevor"'

203. Vitamin D status: Multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient

Author

Lucas, Robyn M., primary, Ponsonby, Anne-Louise, additional, Dear, Keith, additional, Valery, Patricia C., additional, Taylor, Bruce, additional, van der Mei, Ingrid, additional, McMichael, Anthony J., additional, Pender, Michael P., additional, Chapman, Caron, additional, Coulthard, Alan, additional, Kilpatrick, Trevor J., additional, Stankovich, Jim, additional, Williams, David, additional, and Dwyer, Terence, additional

Published
2013
Full Text
View/download PDF

204. The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: The Ausimmune study

Author

Ponsonby, Anne-Louise, primary, Lucas, Robyn M, additional, Dear, Keith, additional, van der Mei, Ingrid, additional, Taylor, Bruce, additional, Chapman, Caron, additional, Coulthard, Alan, additional, Dwyer, Terence, additional, Kilpatrick, Trevor J, additional, McMichael, Anthony J, additional, Pender, Michael P, additional, Valery, Patricia C, additional, and Williams, David, additional

Published
2013
Full Text
View/download PDF

207. EphA4 Receptor Tyrosine Kinase Is a Modulator of Onset and Disease Severity of Experimental Autoimmune Encephalomyelitis (EAE)

Author

Munro, Kathryn M., primary, Dixon, Kirsty J., additional, Gresle, Melissa M., additional, Jonas, Anna, additional, Kemper, Dennis, additional, Doherty, William, additional, Fabri, Louis J., additional, Owczarek, Catherine M., additional, Pearse, Martin, additional, Boyd, Andrew W., additional, Kilpatrick, Trevor J., additional, Butzkueven, Helmut, additional, and Turnley, Ann M., additional

Published
2013
Full Text
View/download PDF

208. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia

Author

van der Mei, Ingrid A F, Ponsonby, Anne-Louise, Dwyer, Terry, Blizzard, Leigh, Taylor, Bruce V, Kilpatrick, Trevor, Butzkueven, Helmut, McMichael, Anthony, van der Mei, Ingrid A F, Ponsonby, Anne-Louise, Dwyer, Terry, Blizzard, Leigh, Taylor, Bruce V, Kilpatrick, Trevor, Butzkueven, Helmut, and McMichael, Anthony

Abstract

Background: Adequate 25(OH)D levels are required to prevent adverse effects on bone health. Population-based data on factors associated with 25(OH)D levels of people with MS have been lacking. Objectives: To examine the prevalence and determinants of vitamin D insufficiency in a population-based sample of MS cases and controls, and to compare 25(OH)D status between MS cases and controls, taking into account case disability. Methods: We conducted a population based case-control study in Tasmania, Australia (latitude 41-43°S) on 136 prevalent cases with MS confirmed by magnetic resonance imaging and 272 community controls, matched on sex and year of birth. Measurements included serum 25(OH)D, sun exposure, skin type, dietary vitamin D intake and disability including EDSS. Results: A high prevalence of vitamin D insufficiency was found in MS cases and controls. Among MS cases, increasing disability was strongly associated with lower levels of 25(OH)D and with reduced sun exposure. Cases with higher disability (EDSS > 3) were more likely to have vitamin D insufficiency than controls (OR = 3.07 (1.37, 6.90) for 25(OH)D ≤ 40 nmol/l), but cases with low disability were not (OR = 0.87 (0.41, 1.86)). Conclusion: The strong associations between disability, sun exposure and vitamin D status indicate that reduced exposure to the sun, related to higher disability, may contribute to the high prevalence of vitamin D insufficiency found in this population-based MS case sample. Active detection of vitamin D insufficiency among people with MS and intervention to restore vitamin D status to adequate levels should be considered as part of the clinical management of MS.

Published
2007

209. Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function

Author

Ponsonby, Anne-Louise, McMichael, Anthony, Van Der Mei, Ingrid, Chapman, Caron, Coulthard, Alan, Dear, Keith, Dwyer, Terry, Kilpatrick, Trevor, Pender, Michael, Taylor, Bruce V, Valery, Patricia C, Williams, David, Lucas, Robyn, Ponsonby, Anne-Louise, McMichael, Anthony, Van Der Mei, Ingrid, Chapman, Caron, Coulthard, Alan, Dear, Keith, Dwyer, Terry, Kilpatrick, Trevor, Pender, Michael, Taylor, Bruce V, Valery, Patricia C, Williams, David, and Lucas, Robyn

Abstract

Rising multiple sclerosis incidence over the last 50 years and geographic patterns of occurrence suggest an environmental role in the causation of this multifactorial disease. Design options for epidemiological studies of environmental causes of multiple

Published
2007

210. Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: Results from the Ausimmune Study.

Author

Hoare, Samuel, Lithander, Fiona, van der Mei, Ingrid, Ponsonby, Anne-Louise, Lucas, Robyn, Chapman, Caron, Coulthard, Alan, Dear, Keith, Dwyer, Terry, Kilpatrick, Trevor, Lucas, Robyn M., McMichael, Tony, Pender, Michael P., Taylor, Bruce, Valery, Patricia C., and Williams, David

Subjects
OMEGA-3 fatty acids, UNSATURATED fatty acids, DEMYELINATION, CENTRAL nervous system, MULTIPLE sclerosis risk factors
Abstract

Background: There is contradictory evidence for a role of dietary fat in risk of multiple sclerosis (MS). Objectives: To examine the association between usual fat intake (total, saturated, monounsaturated (MUFA), polyunsaturated (PUFA), omega-3 and omega-6) and risk of a first clinical diagnosis of CNS demyelination (FCD). Methods: Multi-centre incident case-control study in four regions of Australia during 2003–2006. Cases were aged 18–59 years and had a FCD; controls were matched to a case on age, sex and location. Dietary data were collected using a validated food frequency questionnaire. Results: In 267 cases and 517 controls with dietary data, higher intake (per g/day) of omega-3 PUFA (adjusted odds ratio, AOR=0.61 (95% CI 0.40–0.93)), and particularly that derived from fish (AOR=0.54 (95% CI 0.31–0.93)) rather than from plants (AOR=0.75 (95% CI 0.39–1.43)) was associated with a decreased risk of FCD. Total fat intake and intake of other types of fat were not associated with FCD risk. Conclusions: There was a significant decrease in FCD risk with higher intake of omega-3 PUFA, particularly that originating from fish. There was no evidence to indicate that the intake of other types of dietary fat or fat quantity in the previous 12 months was associated with an altered risk of FCD. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

213. Leukemia Inhibitory Factor Protects Axons in Experimental Autoimmune Encephalomyelitis via an Oligodendrocyte-Independent Mechanism

Author

Gresle, Melissa M., primary, Alexandrou, Estella, additional, Wu, Qizhu, additional, Egan, Gary, additional, Jokubaitis, Vilija, additional, Ayers, Margaret, additional, Jonas, Anna, additional, Doherty, William, additional, Friedhuber, Anna, additional, Shaw, Gerry, additional, Sendtner, Michael, additional, Emery, Ben, additional, Kilpatrick, Trevor, additional, and Butzkueven, Helmut, additional

Published
2012
Full Text
View/download PDF

214. A genome-wide association study in progressive multiple sclerosis

Author

Martinelli-Boneschi, Filippo, primary, Esposito, Federica, additional, Brambilla, Paola, additional, Lindström, Eva, additional, Lavorgna, Giovanni, additional, Stankovich, Jim, additional, Rodegher, Mariaemma, additional, Capra, Ruggero, additional, Ghezzi, Angelo, additional, Coniglio, Gabriella, additional, Colombo, Bruno, additional, Sorosina, Melissa, additional, Martinelli, Vittorio, additional, Booth, David, additional, Oturai, Annette Bang, additional, Stewart, Graeme, additional, Harbo, Hanne F., additional, Kilpatrick, Trevor John, additional, Hillert, Jan, additional, Rubio, Justin P, additional, Abderrahim, Hadi, additional, Wojcik, Jerome, additional, and Comi, Giancarlo, additional

Published
2012
Full Text
View/download PDF

218. Ndrg1 in development and maintenance of the myelin sheath

Author

King, Rosalind H.M., primary, Chandler, David, additional, Lopaticki, Sash, additional, Huang, Dexing, additional, Blake, Julian, additional, Muddle, John R., additional, Kilpatrick, Trevor, additional, Nourallah, Michelle, additional, Miyata, Toshiyuki, additional, Okuda, Tomohiko, additional, Carter, Kim W., additional, Hunter, Michael, additional, Angelicheva, Dora, additional, Morahan, Grant, additional, and Kalaydjieva, Luba, additional

Published
2011
Full Text
View/download PDF

221. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study

Author

van der Mei, Ingrid A F, Ponsonby, Anne-Louise, Dwyer, Terence, Blizzard, Leigh, Simmons, Rex, Taylor, Bruce, Butzkueven, Helmut, Kilpatrick, Trevor, van der Mei, Ingrid A F, Ponsonby, Anne-Louise, Dwyer, Terence, Blizzard, Leigh, Simmons, Rex, Taylor, Bruce, Butzkueven, Helmut, and Kilpatrick, Trevor

Abstract

Objective: To examine whether past high sun exposure is associated with a reduced risk of multiple sclerosis. Design: Population based case-control study. Setting: Tasmania, latitudes 41-3°S. Participants: 136 cases with multiple sclerosis and 272 contro

Published
2003

225. The role of latitude, ultraviolet radiation exposure and vitamin D in childhood asthma and hayfever: an Australian multicenter study

Author

Hughes, Ann Maree, primary, Lucas, Robyn Marjorie, additional, Ponsonby, Anne-Louise, additional, Chapman, Caron, additional, Coulthard, Alan, additional, Dear, Keith, additional, Dwyer, Terry, additional, Kilpatrick, Trevor J., additional, McMichael, Anthony J., additional, Pender, Michael P., additional, Taylor, Bruce V., additional, Valery, Patricia, additional, van der Mei, Ingrid A. F., additional, and Williams, David, additional

Published
2010
Full Text
View/download PDF

226. Latitudinal variation in incidence and type of first central nervous system demyelinating events

Author

Taylor, Bruce V, primary, Lucas, Robyn M, additional, Dear, Keith, additional, Kilpatrick, Trevor J, additional, Pender, Michael P, additional, van der Mei, Ingrid AF, additional, Chapman, Caron, additional, Coulthard, Alan, additional, Dwyer, Terence, additional, McMichael, Anthony J, additional, Valery, Patricia C, additional, Williams, David, additional, and Ponsonby, Anne-Louise, additional

Published
2010
Full Text
View/download PDF

228. Associations between Silicone Skin Cast Score, Cumulative Sun Exposure, and Other Factors in the Ausimmune Study: A Multicenter Australian Study

Author

Lucas, Robyn M., primary, Ponsonby, Anne-Louise, additional, Dear, Keith, additional, Taylor, Bruce V., additional, Dwyer, Terence, additional, McMichael, Anthony J., additional, Valery, Patricia, additional, van der Mei, Ingrid, additional, Williams, David, additional, Pender, Michael P., additional, Chapman, Caron, additional, Coulthard, Alan, additional, and Kilpatrick, Trevor, additional

Published
2009
Full Text
View/download PDF

230. A role for galanin in human and experimental inflammatory demyelination

Author

Wraith, David C., primary, Pope, Robert, additional, Butzkueven, Helmut, additional, Holder, Heidi, additional, Vanderplank, Penny, additional, Lowrey, Pauline, additional, Day, Michael J., additional, Gundlach, Andrew L., additional, Kilpatrick, Trevor J., additional, Scolding, Neil, additional, and Wynick, David, additional

Published
2009
Full Text
View/download PDF

242. Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair

Author

Marriott, Mark P., primary, Emery, Ben, additional, Cate, Holly S., additional, Binder, Michele D., additional, Kemper, Dennis, additional, Wu, Qizhu, additional, Kolbe, Scott, additional, Gordon, Ian R., additional, Wang, Hong, additional, Egan, Gary, additional, Murray, Simon, additional, Butzkueven, Helmut, additional, and Kilpatrick, Trevor J., additional

Published
2008
Full Text
View/download PDF

246. Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients

Author

Rubio, Justin P., primary, Bahlo, Melanie, additional, Stankovich, Jim, additional, Burfoot, Rachel K., additional, Johnson, Laura J., additional, Huxtable, Stewart, additional, Butzkueven, Helmut, additional, Lin, Ling, additional, Taylor, Bruce V., additional, Speed, Terence P., additional, Kilpatrick, Trevor J., additional, Mignot, Emmanuel, additional, and Foote, Simon J., additional

Published
2007
Full Text
View/download PDF

247. A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.

Author

Ben J. Gu, Field, Judith, Dutertre, Sébastien, Ou, Amber, Kilpatrick, Trevor J., Lechner-Scott, Jeannette, Scott, Rodney, Lea, Rodney, Taylor, Bruce V., Stankovich, Jim, Butzkueven, Helmut, Gresle, Melissa, Laws, Simon M., Petrou, Steven, Hoffjan, Sabine, Akkad, Denis A., Graham, Colin A., Hawkins, Stanley, Glaser, Anna, and Bedri, Sahl Khalid

Published
2015
Full Text
View/download PDF

249. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy.

Author

Broadley, Simon A., Barnett, Michael H., Boggild, Mike, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A.L., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith, Taylor, Bruce V., Carroll, William M., and Kilpatrick, Trevor J.

Abstract

In Part 2 of this three part review of multiple sclerosis (MS) treatment with a particular focus on the Australian and New Zealand perspective, we review the newer therapies that have recently become available and emerging therapies that have now completed phase III clinical trial programs. We go on to compare the relative efficacies of these newer and emerging therapies alongside the existing therapies. The effectiveness of β-interferon in the treatment of different stages and the different disease courses of MS is critically reviewed with the conclusion that the absolute level of response in term of annualised relapse rates (where relapses occur) and MRI activity are similar, but are disappointing in terms of sustained disability progression for progressive forms of the disease. Finally we review the controversial area of combination therapy for MS. Whilst it remains the case that we have no cure or means of preventing MS, we do have a range of effective therapies that when used appropriately and early in the disease course can have a significant impact on short term and longer term outcomes. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

250. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations.

Author

Broadley, Simon A., Barnett, Michael H., Boggild, Mike, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A.L., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith, Taylor, Bruce V., Carroll, William M., and Kilpatrick, Trevor J.

Abstract

In this third and final part of our review of multiple sclerosis (MS) treatment we look at the practical day-to-day management issues that are likely to influence individual treatment decisions. Whilst efficacy is clearly of considerable importance, tolerability and the potential for adverse effects often play a significant role in informing individual patient decisions. Here we review the issues surrounding switching between therapies, and the evidence to assist guiding the choice of therapy to change to and when to change. We review the current level of evidence with regards to the management of women in their child-bearing years with regards to recommendations about treatment during pregnancy and whilst breast feeding. We provide a summary of recommended pre- and post-treatment monitoring for the available therapies and review the evidence with regards to the value of testing for antibodies which are known to be neutralising for some therapies. We review the occurrence of adverse events, both the more common and troublesome effects and those that are less common but have potentially much more serious outcomes. Ways of mitigating these risks and managing the more troublesome adverse effects are also reviewed. Finally, we make specific recommendations with regards to the treatment of MS. It is an exciting time in the world of MS neurology and the prospects for further advances in coming years are high. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results